Owlet Management
Management criteria checks 4/4
Owlet's CEO is Kurt Workman, appointed in Jan 2012, has a tenure of 14.42 years. total yearly compensation is $799.41K, comprised of 37.5% salary and 62.5% bonuses, including company stock and options. directly owns 1.83% of the company’s shares, worth $2.47M. The average tenure of the management team and the board of directors is 2.9 years and 5.3 years respectively.
Key information
Kurt Workman
Chief executive officer
US$799.4k
Total compensation
| CEO salary percentage | 37.53% |
| CEO tenure | 14.4yrs |
| CEO ownership | 1.8% |
| Management average tenure | 2.9yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
Narrative Update • Jun 04
OWLT: Softer Q1 Guide Seen Preceding Stronger 2026 Second Half
Narrative Update The analyst price target for Owlet has been reduced from $20 to $15, with analysts pointing to softer Q1 guidance, while also noting 2026 expectations that suggest a more robust back half of that year. What's in the News Owlet launched Dream Sight and Dream Duo 3 across Australia and New Zealand, expanding its full baby monitoring product lineup in those markets, including Dream Sock, Dream Sight, and Dream Duo 3.Seeking Alpha • May 18
Owlet: Telehealth And Subscriptions Could Drive The Next Leg Of Growth
Summary Owlet remains a buy despite mixed Q1 results and lowered revenue guidance, with the stock trading near post-selloff lows. Subscription growth, particularly Owlet 360, is driving higher gross margins, offsetting declining hardware sales and supporting the company’s transition to a pediatric health platform. Profitability guidance improved significantly, with adjusted EBITDA now expected at $7-$9 million, reflecting a sharper focus on profitable markets and cost control. Key risks include slowing hardware sales, elevated operating expenses, and recent CEO turnover, but OWLT’s low valuation and platform evolution offer attractive upside. Read the full article on Seeking AlphaNarrative Update • May 11
OWLT: Softer Q1 Outlook Seen Setting Up Stronger 2026 Finish
Analysts have trimmed their price target on Owlet stock to $15 from $20, citing Q1 guidance that came in below expectations, while highlighting that 2026 guidance still lines up with prior views and points to a potentially stronger second half of that year. Analyst Commentary Bearish analysts are signaling a more cautious stance on Owlet after recent guidance, using the reduced price target as a way to reset expectations while still acknowledging longer term potential.Narrative Update • Apr 20
OWLT: Softer Q1 Outlook Expected To Set Up Stronger Second Half 2026
Analysts have lowered their price target on Owlet to $15 from $20, citing slightly softer Q1 guidance versus expectations. They also note that current management guidance indicates the second half of 2026 could be more robust.Narrative Update • Apr 05
OWLT: Guidance And Partnerships Are Expected To Support A Stronger Second Half 2026
Analysts have revised Owlet's price target to $15, down from $19, reflecting mixed near term guidance and updated models that still indicate the possibility of stronger performance in the longer term. Analyst Commentary Recent research updates on Owlet point to a more cautious tone, even as some longer term expectations remain in place.Narrative Update • Mar 22
OWLT: Updated Modeling And Healthcare Partnerships Will Support Stronger Second Half 2026
Analysts have updated their view on Owlet, trimming the consolidated price target to $15 as they factor in softer Q1 guidance, a higher assumed P/E multiple and lower projected revenue growth and profit margins, while still highlighting expectations for a stronger second half of 2026. Analyst Commentary Recent research highlights a more measured tone around Owlet, with some price targets recalibrated as analysts balance solid past execution with softer near term guidance and updated valuation assumptions.Narrative Update • Mar 08
OWLT: Updated Modeling And New Healthcare Partnerships Will Support Future Upside Potential
Analysts have adjusted their outlook on Owlet, trimming the price target from $14 to $13 as they factor in updated expectations for growth, profitability, and future P/E assumptions that are informed by recent research highlighting mixed near term guidance alongside longer term projections that are described as steady. Analyst Commentary Recent Street research reflects a mixed but increasingly cautious tone around Owlet, with some bearish analysts trimming price targets as they reassess growth visibility and execution risk against current valuation.Narrative Update • Feb 22
OWLT: Updated Modeling And FDA Pathways Will Support Future Upside Potential
Analysts have lifted their price target on Owlet to $19 from $15, citing updated modeling assumptions following a transfer of coverage. Analyst Commentary Recent research points to a reset in expectations around Owlet, with updated modeling used to support a US$19 price target.
Narrative Update • Feb 07
OWLT: Additional Liquidity And Partnerships Will Extend Funding Runway
Analysts have lifted their price target on Owlet to US$20 from US$15, citing updated models that factor in recent Street research highlighting a refreshed coverage framework and additional liquidity that supports the company’s plans. Analyst Commentary Bullish analysts are pointing to recent price target revisions as a sign of growing confidence in Owlet’s ability to execute on its plans, especially as fresh research coverage and additional liquidity are incorporated into updated models.Analysis Article • Feb 05
Some Owlet, Inc. (NYSE:OWLT) Shareholders Look For Exit As Shares Take 31% Pounding
Owlet, Inc. ( NYSE:OWLT ) shares have retraced a considerable 31% in the last month, reversing a fair amount of their...
Narrative Update • Jan 24
OWLT: Liquidity And New Coverage Models Will Support Future Execution
Narrative Update: Owlet Analyst Price Target Shift Analysts have lifted their price target on Owlet from US$16 to US$17, reflecting updated models that factor in recent target increases on the Street and comfort with assumptions around fair value, discount rate, and a higher future P/E multiple. Analyst Commentary Recent Street research has tilted constructive on Owlet, with bullish analysts lifting price targets and updating their models following new company information and a transfer of coverage.Narrative Update • Jan 09
OWLT: Liquidity And Regulatory Progress Will Support Execution While Risks Remain
Analysts have lifted their price target on Owlet to US$16.00 from US$14.88, citing refreshed models that factor in recent price target increases from firms updating coverage and highlighting added liquidity to support R&D into 2026. Analyst Commentary Recent Street research has trended constructive on Owlet, with higher price targets reflecting refreshed coverage models and a focus on liquidity and execution into 2026.Narrative Update • Dec 15
OWLT: FDA Focus And Global Expansion Will Shape Balanced Risk Profile
Analysts have raised their fair value estimate for Owlet from $11.00 to $14.00 per share, citing stronger projected revenue growth, improved liquidity from a recent stock offering, and an FDA highlighted competitive moat that supports a higher long term price target. Analyst Commentary Recent research commentary has underscored a more constructive outlook on Owlet, with price targets moving higher following what was described as a solid quarter and improved balance sheet flexibility.Analysis Article • Dec 05
There's Reason For Concern Over Owlet, Inc.'s (NYSE:OWLT) Massive 67% Price Jump
Owlet, Inc. ( NYSE:OWLT ) shares have continued their recent momentum with a 67% gain in the last month alone. The...Narrative Update • Dec 01
OWLT: Regulatory Momentum And FDA Approval Will Drive Market Leadership Forward
Analysts have increased their price target for Owlet to $15.50 from $12.00, citing a solid quarter, improved liquidity, and the company's status as the only FDA-approved over-the-counter infant monitoring device as key drivers for their more favorable outlook. Analyst Commentary Recent analyst perspectives on Owlet reflect a mixed but largely positive sentiment following the company's most recent financial results and regulatory developments.Narrative Update • Nov 17
OWLT: Regulatory Approvals And Increased Liquidity Will Support Long-Term Market Leadership
Analysts have raised their price target for Owlet from $13.20 to $14.83. They cite stronger revenue growth, improved profitability, and increased liquidity following the company's solid recent quarter.Analysis Article • Oct 07
Further Upside For Owlet, Inc. (NYSE:OWLT) Shares Could Introduce Price Risks After 31% Bounce
Owlet, Inc. ( NYSE:OWLT ) shares have had a really impressive month, gaining 31% after a shaky period beforehand. The...Narrative Update • Aug 09
Telehealth Partnerships And AI Insights Will Broaden Digital Health Markets
Driven by strong consumer demand for its FDA-cleared Dream Sock and a unique competitive position, analysts have raised Owlet’s price target from $12.30 to $13.20. Analyst Commentary The $300 Dream Sock is currently a best-selling smart baby monitor on Amazon, demonstrating strong consumer traction.Analysis Article • Jun 14
Investors Still Aren't Entirely Convinced By Owlet, Inc.'s (NYSE:OWLT) Revenues Despite 34% Price Jump
Owlet, Inc. ( NYSE:OWLT ) shares have continued their recent momentum with a 34% gain in the last month alone. The last...
New Narrative • Apr 10
Dream Sock, BabySat, And Company360 Will Expand Global Healthcare Access
Owlet's FDA and CE approvals pave the way for global market expansion, boosting international revenue potential.Analysis Article • Oct 18
Many Still Looking Away From Owlet, Inc. (NYSE:OWLT)
Owlet, Inc.'s ( NYSE:OWLT ) price-to-sales (or "P/S") ratio of 1x might make it look like a strong buy right now...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$48m |
| Dec 31 2025 | US$799k | US$300k | -US$42m |
| Sep 30 2025 | n/a | n/a | -US$42m |
| Jun 30 2025 | n/a | n/a | -US$52m |
| Mar 31 2025 | n/a | n/a | -US$17m |
| Dec 31 2024 | US$987k | US$375k | -US$17m |
| Sep 30 2024 | n/a | n/a | -US$11m |
| Jun 30 2024 | n/a | n/a | -US$11m |
| Mar 31 2024 | n/a | n/a | -US$19m |
| Dec 31 2023 | US$269k | US$267k | -US$33m |
| Sep 30 2023 | n/a | n/a | -US$49m |
| Jun 30 2023 | n/a | n/a | -US$61m |
| Mar 31 2023 | n/a | n/a | -US$63m |
| Dec 31 2022 | US$5m | US$369k | -US$79m |
| Sep 30 2022 | n/a | n/a | -US$84m |
| Jun 30 2022 | n/a | n/a | -US$99m |
| Mar 31 2022 | n/a | n/a | -US$93m |
| Dec 31 2021 | US$2m | US$330k | -US$72m |
Compensation vs Market: Kurt's total compensation ($USD799.41K) is about average for companies of similar size in the US market ($USD641.77K).
Compensation vs Earnings: Kurt's compensation has been consistent with company performance over the past year.
CEO
Kurt Workman (36 yo)
14.4yrs
Tenure
US$799,405
Compensation
Mr. Kurt Workman co-founded Owlet Baby Care Inc. (formerly Owlet Baby Care LLC) in 2012 and served as the Chief Executive Officer from its founding in 2012 until December 2019. He was President of Owlet, I...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 14.4yrs | US$799.41k | 1.83% $ 2.5m | |
| Chief Financial Officer | 1.9yrs | US$2.42m | 0.57% $ 767.9k | |
| Chief Operating Officer | no data | no data | no data | |
| Chief Technology Officer | 4.4yrs | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Chief Parent Officer | 2.9yrs | no data | no data | |
| Chief Revenue Officer | 1yr | no data | no data |
2.9yrs
Average Tenure
Experienced Management: OWLT's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 13.9yrs | US$799.41k | 1.83% $ 2.5m | |
| Independent Director | 5.3yrs | US$213.37k | 0.31% $ 414.8k | |
| Independent Director | 5.3yrs | US$245.87k | 0.28% $ 380.6k | |
| Independent Director | 5.2yrs | US$213.37k | 0.80% $ 1.1m | |
| Independent Director | 2.8yrs | US$213.37k | no data | |
| Independent Chairman of the Board | 10.9yrs | no data | no data | |
| Independent Director | 2.9yrs | US$213.37k | 0.24% $ 321.1k | |
| Independent Director | 8.2yrs | no data | no data |
5.3yrs
Average Tenure
55yo
Average Age
Experienced Board: OWLT's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/16 11:25 |
| End of Day Share Price | 2026/06/16 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Owlet, Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Allen Lutz | BofA Global Research |
| James Suva | Citigroup Inc |
| Ilya Zubkov | Freedom Broker |